It is good to see plans documented even if the contents are largely known.
The star on the horizon I see is the option to licence agreement with Novartis - and there's comfort in Epichem expanding and bolstering the share price in the interim. A strategic partnership such as this would really light things up.
The investment newsletter 'Bioshares' released last night covered PAA. They provided a good summary of the business. Interestingly the article highlighted the recent patent for mTOR diseases as they believed this may have potential to unlock greater value than the overcrowded cancer drug development area.
Ann: PharmAust Shareholders Update and Roadmap, page-2
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
0.010(5.13%) |
Mkt cap ! $99.65M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 20.5¢ | 19.5¢ | $95.38K | 475.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 135256 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 79851 | 3 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |